Purinergic signaling has been recognized as playing an important role in inflammation, angiogenesis, malignancy, diabetes and neural transmission. Activation of signaling pathways downstream from purinergic receptors may also be implicated in transplantation and related vascular injury. Following transplantation, the proinflammatory "danger signal" adenosine triphosphate (ATP) is released from damaged cells and promotes proliferation and activation of a variety of immune cells. Targeting purinergic signaling pathways may promote immunosuppression and ameliorate inflammation. Under pathophysiological conditions, nucleotide-scavenging ectonucleotidases CD39 and CD73 hydrolyze ATP, ultimately, to the antiinflammatory mediator adenosine. Adenosine suppresses proinflammatory cytokine production and is associated with improved graft survival and decreased severity of graft-versus-host disease. Furthermore, purinergic signaling is involved both directly and indirectly in the mechanism of action of several existing immunosuppressive drugs, such as calcineurin inhibitors and mammalian * Corresponding authors: Markus Dworak and Simon C. Robson, markus.dworak@novartis.com and srobson@bidmc.harvard.edu.
mammalian target of rapamycin (mTOR) inhibitors, mycophenolic acid (MPA) or calcineurin inhibitors (CNIs), are closely linked to cell metabolism and might affect, and simultaneously be affected by, purinergic signals. The purpose of this review was to explore the role of purinergic signaling in transplantation and immunosuppression and the implications for clinical practice.
Purinergic Signaling in Specific Organs, Tissues, and Cells Liver
Purinergic signaling is implicated in a variety of liver diseases and posttransplantation outcomes such as inflammation, rejection, hepatic IRI, hepatic regeneration, steatohepatitis, fibrosis, and cancer (15) (16) (17) (18) (19) (20) . The liver produces the majority of the nucleotides in the body and concurrently has high ATPase and ADPase activities. Mechanical stress during transplantation results in the secretion of ATP or ADP from hepatocytes and Kupffer cells, which subsequently bind P2X and P2Y receptors expressed on hepatocytes, hepatic sinusoids and other resident cells or bind P1 receptors following hydrolysis to adenosine by selected ectonucleotidases (Figure 2 ) (reviewed by Burnstock et al [21] ). Although adenosine can promote immunosuppression through the proliferation and activation of Tregs via activation of the P1A2a receptor (reviewed by Roberts et al [22] ), protracted ectonucleotidase-dependent adenosine production following ethanol or fructose ingestion can lead to hepatic steatosis, fibrosis and, ultimately, cirrhosis. These diverse biological effects of adenosine have important implications for the development of purinergic therapies in liver transplantation (21) . CD39 is important for rapid posttransplant hepatic regeneration and subsequent graft outcomes, as shown by the reduced regenerative capacity of liver transplanted into CD39-deficient mice (reviewed by Beldi et al [19] ). Transgenic CD39 has also been shown to be beneficial in protecting liver grafts from early IRI in mice after 18 h of cold ischemia, an effect attributed to the depletion of hepatic CD4 + T cells but not NK T cells that may have a greater role in warm IRI (23) . Monitoring hepatic ATP levels in conjunction with serum hyaluronic acid has been suggested as an approach to assess graft viability and posttransplant instability (reviewed by Vaughn et al [24] ). The Immu-Know assay (Cylex, Inc., Columbia, MD), which measures peripheral blood CD4 + total ATP levels, has shown promise in determining immunosuppression and diagnosing early rejection (21) .
Kidney
Purinergic P2X and P2Y receptors are expressed on a variety of renal cells, including mesangial cells, podocytes and cells of the parietal sheets ( Figure 2 ), and all renal cells can produce ATP under conditions such as mechanical or osmotic stress, fluid flow or agonist stimulation (25, 26) . Furthermore, overexpression of the ectonucleotidase CD39 protected against renal IRI in a mouse model, raising the possibility that soluble CD39 (e.g. apyrase) could be used therapeutically to prevent organ damage in kidney transplantation (8, 27) .
In a renal transplantation model characterized by 5 h of cold preservation, mice receiving a CD39-overexpressing graft had better renal function and remained healthy for a longer duration compared with the control recipients. This effect was attributed to the increased production of adenosine in these mice, and the P1A2a receptor may also be involved because blocking this receptor with a specific antagonist reversed the observed benefits (28) . In the same study, transgenic expression of human CD39 conferred renal protection in a mouse model of warm IRI, and together with results from the transplantation model, the authors concluded that CD39 expression had beneficial effects on both warm and cold renal IRI (28) .
Other studies have shown that P1A2a receptor activation considerably reduces T cellmediated renal injury (22) . The P1A2b receptor was shown to protect against tissue injury and to improve kidney function in a mouse model of renal ischemia using ischemic preconditioning, an effect attributed to the inhibition of neutrophil-dependent production of tumor necrosis factor α (TNF-α) (29, 30) . A recent review by Solini et al gives a more detailed overview of the involvement of ATP and P2 receptors in both physiological and pathological signaling in the kidney (31) .
Heart
Some of the earliest work on the extracellular action of purines was performed on heart and blood vessels (32) (33) (34) , and it is known that cardiac cells express purinergic receptors and ectonucleotidases ( Figure 2 ) (22) . An in vitro cardiac cell ischemia model showed that adenosine prevented necrosis and promoted cardioprotection through P1A2a/2b receptor activation (35) . Furthermore, adenosine-treated grafts in a rat heterotopic heart transplant model showed less inflammation and fewer infiltrating cells, with reduced subsequent IRI and myocardial injury compared with the control grafts (36) . This effect suggests that storing and transporting grafts in the presence of adenosine, as in UW solution, may reduce the impact of IRI and improve graft outcomes (22) . Furthermore, cardiac xenograft rejection and vascular thrombosis observed in mice was reversed when CD39 was introduced either by adenovirus-mediated overexpression (37) or administration of apyrase (38) . Similarly, CD39 has been shown to be cardioprotective by reducing myocardial infarction following P1A2b-mediated coronary artery occlusion (22) . Studies in a cardiac allotransplantation model demonstrated that reduced graft expression of P1A2b increased inflammatory and immune responses and ultimately reduced allograft survival when either the donor or recipient was CD73 deficient, demonstrating the protective effect of CD73 (39) .
Targeting of the P2X7R receptor with oxidized ATP (oATP) was shown to promote cardiac transplant survival in 80% of murine recipients of a fully mismatched allograft, an effect that correlated with the inhibition of T cell activation and differentiation (40) .
Lung
Pulmonary and alveolar epithelial cells express purinergic receptors and ectonucleotidases ( Figure 2 ) (22, 41, 42) , and purinergic signaling is known to contribute to the pathophysiology of asthma and chronic obstructive pulmonary disease (reviewed by Adriaensen and Timmermans [43] ). Inhibition of P2X7 signaling through the use of oATP, a specific P2X7 inhibitor, resulted in fewer inflammatory cells, less rejection, improved lung function, and prolonged survival of lung allografts in mice (44) . The suppression of inflammation by CD73-mediated adenosine production, particularly through the P1A2a receptor, is known to be crucial in graft survival and lung function (22) . In a porcine model of lung transplantation, activation of the P1A2a receptor during early reperfusion limited inflammation and preserved lung function (45) . Conversely, it has been suggested that activation of the P1A2b receptor may promote bronchiolitis obliterans syndrome, a manifestation of chronic pulmonary allograft dysfunction (46) . These findings suggest that a P1A2a receptor agonist, possibly coupled with a P1A2b receptor antagonist, might be beneficial in limiting acute pulmonary IRI and subsequently improving graft survival and lung function following transplantation.
Pancreatic islets
Expression of purinergic receptors on islet beta cells has been documented ( Figure 2 ) and plays a definitive role in insulin secretion (47, 48) , whereby elevated extracellular ATP levels have been associated with hyperinsulinemia (49) . A recent study by Vergani and colleagues reported the expression of P2X7 receptors on islets and subsequent inhibition of this purinergic receptor using oxidized ATP in mouse models of islet allograft rejection (50) . This intervention resulted in significant improvement in graft survival, with 30% of the mice maintaining good graft function at 100 days. Furthermore, when combined with sirolimus, the intervention resulted in favorable long-term graft outcomes at 100 days in 7 of the 10 mice. In another transplantation model, human CD39 overexpression in transgenic islets significantly delayed clot formation time in the presence of human blood, prolonging graft islet viability (51) .
The immunosuppressive effect of adenosine in inhibiting interferon γ production from neutrophils has been shown to prevent early loss of transplanted islets in the livers of mice (52) . Another study using a multiple low-dose streptozotocin mouse model reported that overexpression of CD39, which promotes the production of adenosine, protected islet grafts from T cell-mediated injury and reduced susceptibility to diabetes (53) .
Endothelium
Extracellular ATP is rapidly broken down by ectoenzymes (54) , such as the nucleoside triphosphate diphospho-hydrolase family, including NTPDase 1 (CD39), the nucleotide pyrophosphatase/phosphodiesterase family, ecto-5′-nucleotidase (CD73), and alkaline phosphatase (9, (55) (56) (57) . CD39 is expressed on quiescent endothelial cells playing a critical role in thromboregulation (58) , whereas NTPDase 2 is widely expressed on vascular adventitial cells ( Figure 2 ) (59).
In episodes of chronic rejection, the endothelial layer is invariably damaged, triggering a collateral pathway of coagulation mediated primarily through thrombin, a potent platelet agonist. The downstream effects of thrombin are mediated through protease-activated receptors (reviewed by Shrivastava et al [60] ) and lead to the activation of platelets, endothelial cells and a wide array of immune cells. This response is synergistically augmented through the release of ADP by activated platelets and endothelial cells from dense intracellular granules, resulting in ectonucleotidase-mediated production of AMP and adenosine.
Bearing in mind the destructive effects of thrombus formation in mediating transplant rejection and its biological pathways of formation, one can appreciate the role of ectonucleotidases in modulating allograft responses. The activity of CD39 has been reported to be significantly decreased in chronic rejecting grafts, highlighting a potentially therapeutic avenue of complementation. The viability of this prospect was confirmed in mouse models of rejection in conjunction with transgenic expression of human CD39. In this study, mice overexpressing human CD39 had increased cardiac allograft survival along with protection from thrombosis compared with wild type (WT) mice, serving only to further highlight the previously untapped antithrombotic therapeutic potential of ectonucleotidases in transplantation (61) .
Stem cells: mesenchymal and hematopoietic
Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative therapeutic option for patients with hematological cancers, is performed >27 000 times globally per year (62); however, GvHD remains a major obstacle for a broader application of allo-HSCT. Extracellular nucleotides and ectonucleotidases are involved in inflammation (reviewed by Deaglio and Robson [12] ) and can be particularly implicated in GvHD (63, 64) . Interestingly, multiple studies show that mesenchymal stromal/stem cells (MSCs), which have the potential to upregulate CD39 and CD73 ( Figure 2 ) and to increase adenosine production to suppress activated T cells (65), promote tolerance following allo-HSCT (66-70), diabetes (71) , and solid organ transplantation (72) .
A recent publication has shown that suppressive-type MSCs can be induced by IL-17A and promote the generation of CD4 + CD25 high CD127 low FoxP3 + Tregs (iTregs) from activated CD4 + CD25 − T cells in vitro. These induced iTregs express both CD39 and CD73 as well as CD69, OX40, cytotoxic T lymphocyte-associated antigen 4, and glucocorticoid-induced TNF receptor-related protein. The generated, suppressive MSCs are thus able to boost iTreg functionality to potently suppress T cell activation and appear to have minimal immunogenicity. These MSCs and other regulatory cells might be considered a potential option for patients with corticosteroid-refractory GvHD (73) .
Impact of Purinergic Signaling on Immunosuppressive Drugs

Calcineurin inhibitors
The serine/threonine phosphatase calcineurin has a role in the activation of T cells, and inhibition of this protein by CNIs is a widely used treatment strategy to promote immunosuppression following transplantation. Cyclosporine forms a complex with the cytosolic protein cyclophilin, which binds and inactivates calcineurin and ultimately inhibits the transcription of IL-2 and other proinflammatory cytokines by preventing calcineurindependent dephosphorylation of the transcription factor nuclear factor of activated T cells (NFAT) ( Figure 3 ) (74, 75) . Tacrolimus, also known as FK506, inhibits NFAT dephosphorylation by calcineurin, although the precise mechanism of action differs from that of cyclosporine. Tacrolimus binds to the immunophilin FKBP12, forming an FKBP12-FK506 complex that inactivates calcineurin (74, 75) .
ATP signaling through the P2Y2 receptor dose-dependently increased NFAT activity and intracellular Ca 2+ in rat neonatal cardiac fibroblasts, with an associated decrease in angiotensin type 1 receptor. This effect of ATP was inhibited by the addition of cyclosporine, indicating that ATP-mediated NFAT induction is achieved through the calcineurin-NFAT pathway and thus is inhibited by CNIs (76) . Inhibition of the P1A3 adenosine receptor with theophylline improved glomerular filtration rate and renal blood flow in an acute tacrolimus toxicity model in rats, suggesting a role for pathological levels of adenosine in nephropathies associated with CNI treatment (77) .
Mycophenolic acid
Mycophenolate mofetil is an antiproliferative agent that is metabolized to MPA and inhibits the synthesis of guanine monophosphate, thereby blocking the proliferation of B and T lymphocytes. MPA achieves this effect by binding and inhibiting the enzyme inosine monophosphate dehydrogenase, the crucial enzyme of de novo purine synthesis ( Figure 3 ) (78, 79) . Because of this mechanism of action, MPA has a direct inhibitory effect on the synthesis of purines and thus can modify the amount of eATP that is available for purinergic signaling. MPA treatment in a primary human T lymphocyte model resulted in up to 50% reduction in ATP concentration in comparison to control cells (80) .
mTOR inhibitors
The mTOR inhibitors sirolimus and everolimus block the activity of mTOR, a serine/ threonine protein kinase with multifarious physiological roles in regulating cell metabolism, growth, proliferation, angiogenesis and immune responses. Both sirolimus and everolimus are similar to tacrolimus in that they bind to the immunophilin FKBP12; however, rather than inhibiting calcineurin, the FKBP12-sirolimus or FKBP12-everolimus complex inhibits the activity of mTOR ( Figure 3 ) (reviewed by Klintmalm and Nashan [81] ).
The relative levels of ATP and adenosine in the extracellular space can directly influence the activation or inhibition of mTOR and the subsequent induction of either proinflammatory or anti-inflammatory responses, respectively (reviewed by Cobbold [82] ). mTOR is known to be an important downstream effector protein in purinergic signaling, and mTOR phosphorylation is a required step in ATP-induced cell proliferation, which can be inhibited by rapamycin/sirolimus and other mTOR inhibitors (e.g. AZD8055) that compete with ATP at the mTOR-active site (83, 84) . Treatment of mice with rapamycin/sirolimus in combination with oATP, an irreversible P2X7 purinergic receptor inhibitor, resulted in longterm islet function in 80% of transplanted mice, suggesting a synergistic effect between mTOR inhibitors and purinergic inhibitors that might be beneficial following transplantation in humans (50) .
When combined with the CNI cyclosporine, sirolimus treatment enhanced cyclosporineinduced inhibition of purinergic metabolism compared with cyclosporine alone in perfused rat brain slices after 4 h of perfusion, suggesting synergistic immunosuppressive activity between the CNI and the mTOR inhibitor (85); however, this synergistic effect was not observed following similar combination treatment with cyclosporine and everolimus. Increasing blood concentrations of sirolimus decreased relative Krebs cycle urine metabolite 
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Other immunosuppressants
The anti-CD25 monoclonal antibody basiliximab binds to the IL-2 receptor α chain ( Figure  3 ), thereby inhibiting purinergic signaling and other pathways leading to IL-2-mediated proliferation of T cells and allograft rejection (reviewed by McKeage and McCormack [87] ). The anti-CD40 monoclonal antibody lucatumumab acts by preventing the interaction between CD40 and CD40 ligand and thus inhibiting the presentation of antigen to T cells. Interestingly, low concentrations of eATP have been shown to interfere with the same target as lucatumumab, the CD40-CD40 ligand complex and subsequently inhibit the activation of T cells by dendritic cells (88) . Other antibody-based drugs used as immunosuppressants in transplantation include antithymocyte globulin (polyclonal), alemtuzumab (anti-CD52), and rituximab (anti-CD20) (reviewed by van Sandwijk et al [89] ). A recent review by Cekic and Linden gives a detailed overview of purinergic signaling in specific immune cells following tissue injury (90) .
Relevance in Preclinical Research and for Clinical Practice
Ectonucleotidases (CD39/CD73)
As described in the preceding sections, CD39 and CD73 are both abundantly expressed on Tregs (91, 92) , which allows them to hydrolyze the proinflammatory danger signal ATP to the anti-inflammatory mediator adenosine. Evidence of this protective role of CD39 was observed in a skin allograft rejection model in which the adoptive transfer of Tregs from CD39-deficient mice failed to prevent skin allograft rejection compared with the transfer of WT Tregs (92) .
This protective effect of CD39 appears to involve adenosine production because activation of the adenosine 2A receptor has been shown to enhance survival of skin allografts in mice (93) . Several immune cells express CD73, such as subsets of B and T lymphocytes (94), Tregs (92) and MSCs (95) but also intestinal epithelial cells (96) and endothelial cells of capillaries and venules (97) . CD73 generates nucleosides for the purine salvage pathway; neighboring cells can take up the nucleosides via facilitated diffusion and use the molecules to recover nucleic acid bases and subsequently synthesize new nucleotides to meet critical metabolic needs of the cell. In addition, CD73 generates adenosine, which activates the seven-transmembrane domain G protein-coupled P1 purinergic (adenosine) receptors.
The P1A1 and P1A3 receptors bind to a G i protein and cause a reduced intracellular concentration of cyclic AMP (cAMP) by inhibiting adenylyl cyclase, whereas the P1A2a and P1A2b receptors bind to a G s protein and increase the intracellular concentration of cAMP by stimulating adenylyl cyclase. In addition, P1A2b and P1A3 receptors can interact with a G q protein and stimulate phospholipase C (reviewed by Hasko et al [98] ). Signaling cascades of adenosine receptors, however, are much more complex because they have also been shown to modulate protein kinase C, phosphoinositide 3 kinase and mitogen-activated protein kinases (reviewed by Jacobson and Gao [99] ). P1 receptors have individual affinities toward their substrate. Although the half maximal effective concentration (EC 50 ) of the P1A1, P1A2a, and P1A3 receptors is 0.01-1.00 μM, activation of the P1A2b receptor requires adenosine levels >10 μM (EC 50 24 μM). This means that the P1A2b receptor is not activated under physiological conditions but rather plays a role only when adenosine concentration is increased because of cellular stress, such as in the case of inflammation (98) .
In the majority of clinically relevant models, adenosine provides an anti-inflammatory signal and counteracts the proinflammatory reactions induced by the presence of ATP in the extracellular space. CD73 and its product adenosine have also been implicated as regulatory mechanisms in rejection of cardiac and tracheal allografts. In a model of heterotopic murine cardiac transplantation, CD73 deficiency of either the donor or the recipient resulted in significantly reduced allograft survival (39) . These observations are consistent with results from earlier studies that showed involvement of adenosine in the suppression of proinflammatory cytokine production (100,101). In addition, 60 days after transplantation, CD73-deficient allografts showed more severe luminal occlusion in the graft coronary arteries correlating to cardiac allograft vasculopathy as well as significantly higher levels of donor-reactive alloantibodies in the chronic rejection phase. These effects were, at least in part, mediated by the P1A2b receptor.
The role of CD73 and endogenous adenosine was investigated in a study of murine acute GvHD with an MHC major mismatch between donor and recipient (64) . A CD73 deficiency in either donor or recipient mice resulted in significantly more severe GvHD, with reduced survival of the recipient, increased GvHD histopathology scores and increased concentrations of IL-6 and interferon γ in the serum of recipient mice compared with WT mice. Furthermore, deletion of CD73 resulted in increased proliferation of alloreactive CD4 + and CD8 + T cells. These data are consistent with previous reports showing that even low concentrations of extracellular adenosine and other P1 receptor agonists inhibit T cell activation and expansion via binding to the P1A2a receptor (102) . Furthermore, endogenous adenosine binding to the P1A2a receptor limited the expansion of alloreactive T cells and dampened the severity of acute GvHD. These findings extend those from previous studies (103) that suggested activation of the P1A2a receptor via the selective agonist ATL146e improved the survival of GvHD mice without affecting donor cell engraftment. Moreover, the treatment of T cells with ATL146e reduced in vitro migration toward the chemokines CCL20, CXCL12 and CXCL10 by at least 30%, whereas in vivo administration of ATL146e decreased the serum levels of various proinflammatory cytokines. P1A2a receptor activation also improved the clinical condition of mice with already established GvHD by reversing weight loss (103) .
Organ and graft heterogeneity
Transplant rejection due to organ and graft heterogeneity is a major obstacle in clinical practice, and strategies to improve tolerance include the suppression of T and B cell effector functions in addition to the activation of immunosuppressive Tregs (104) . Lung, cardiac, renal and liver allografts (and xenografts) exhibit quite distinct patterns of vascular inflammation and thrombosis that may dictate differential outcomes following transplantation. In prior studies of pig-to-primate xenotransplantation, protective-type genes (heme oxygenase I, superoxide dismutases and CD39), together with thromboregulatory genes such as von Willebrand factor and P-selectin, were noted to be substantially upregulated in renal grafts that were associated with platelet consumption (105) . In cardiac xenografts, fibrin deposition was quite marked and associated with increased plasminogen activator inhibitor 1 expression. The different outcomes observed in clinical practice might reflect overall differences in gene expression profiles, including those of purinergic signaling components, in renal and cardiac grafts (105, 106) .
Xenotransplantation
The use of xenotransplantation in clinical practice has the potential to overcome the shortfall of available human organs and tissues for patients that urgently require transplantation (107, 108) . In the United States alone, 18 potential transplant recipients die every day due to a lack of critical organs (reviewed by Michel et al [109] ). The pig is often cited as the most suitable source of xenografts (reviewed by Ekser et al [110] ). Research into the genetic manipulation of pigs to reduce xenograft rejection has focused largely on removing the Gal antigen from the surface of xenotransplant cells (109) . Increasing the expression of human CD39 and CD73 is also considered a potential strategy to prevent xenograft rejection by increasing the hydrolysis of ATP to adenosine and promoting immunosuppression (107, 111) . In addition, CD39 is known to exert anticoagulant/antithrombotic properties that may further aid in preventing xenograft rejection.
The current model for the pathogenesis of acute GvHD suggests that the disease develops in three stages. The first phase in acute GvHD is triggered by the cytotoxic chemotherapy or irradiation therapy of the recipient. This treatment causes necrotic and apoptotic cell death, particularly in the intestinal tract, leading to intestinal barrier breakdown, with subsequent activation of a local immune response including macrophages and other antigen-presenting cells (APCs). Consequently, proinflammatory cytokines like TNF-α and IL-1β are released, and neutrophil granulocytes are recruited into the intestinal tract, a process driven by the translocation of pathogen-associated molecular patterns, such as bacterially derived lipopolysaccharide. In addition to these infectious stimuli, tissue destruction after the preconditioning treatment leads to release of specific noninfectious danger-associated molecular patterns, such as ATP (reviewed by Zeiser et al [112] ). These signals activate the innate immune system of the host, especially the APCs, via interaction with purinergic, Tolllike or nucleotide oligomerization domain-like receptors.
In the second phase of GvHD, transplanted donor T cells interact with APCs, most importantly with dendritic cells (113) . Local proinflammatory cytokines produced in the first GvHD phase serve as further stimuli for activation, differentiation and proliferation of the donor-derived T cells (reviewed by Zeiser et al [114] ). In the third GvHD phase, after initial expansion the differentiated effector cells, mostly T cells but also NK cells, macrophages and neutrophils, migrate to the target tissues of GvHD (e.g. skin, gastrointestinal tract, and liver) and cause tissue destruction. ATP was recently shown to be released from necrotic cells after the preconditioning treatment prior to allo-HSCT, and that serves as a critical danger signal for the activation of the immune system (63) . Results from in vivo and in vitro 
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Conclusions
Purinergic signaling is closely associated with the regulation and direction of inflammation and local immune responses; therefore, targeting the purinergic signaling pathway by increasing ectonucleotidase activity and/or boosting short-term adenosine-mediated immunosuppression holds great potential for preventing allograft vascular injury, thereby ameliorating rejection and promoting tolerance. Existing immunosuppressive agents such as CNIs, MPA and mTOR inhibitors can interact with purinergic signaling pathways either directly or indirectly. These interactions provide great opportunities for the design of possible combination therapies with purinergic receptor agonists/antagonists to further manipulate and optimize immunosuppression in transplantation.
Based on studies in transplantation models, CD39 and other components of purinergic signaling pathways may be considered potentially crucial regulators of vascular inflammation, thrombosis and tolerance induction. Consequently, further studies to increase our understanding of purinergic signaling in transplantation are of vital importance to clinical practice. Intracellular ATP is released from cells through the opening of pannexin hemi channels or via P2X7 receptors and can serve as an extracellular signaling molecule. ATP subsequently signals with various P2 receptors, both ligand-gated P2X and G protein-coupled P2Y receptors, in an autocrine manner, which has been implicated in a wide variety of physiological processes. Eventually, ATP is hydrolyzed by ENTPDases expressed on cell surfaces, including CD39 and the ecto-5′-nucleotidase CD73, which promote the generation of adenosine. Adenosine signals on G protein-coupled P1 receptors and is metabolized to inosine by the enzyme adenosine deaminase. ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate.
Figure 2. Distribution of purinergic receptors
An overview of purinergic receptor CD39 and CD73 expression is shown in selected organs, tissues, and cells. Further information on the distribution of purinergic receptors can be found in Table 1 . 
